Nanomedicine for targeting brain Neurodegeneration: Critical barriers and circadian rhythm Considerations
Name
1-s2.0-S0169409X25000912-main.pdf
Description
Published version
Size
5.23 MB
Format
Adobe PDF
Checksum (MD5)
2c894987e71a0630e198dc4b56a77cc8
Author(s)
Pineiro-Alonso, Laura
Rubio-Prego, Inés
Lobyntseva, Alexandra
González-Freire, Eva
Langer, Robert
Alonso, María José
Date Issued
July 2025
Journal
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Citation
Pineiro-Alonso, Laura, Rubio-Prego, Inés, Lobyntseva, Alexandra, González-Freire, Eva, Langer, Robert et al. 2025. "Nanomedicine for targeting brain Neurodegeneration: Critical barriers and circadian rhythm Considerations." Advanced Drug Delivery Reviews, 222.
Version
Final published version
Abstract
The development of novel therapies for central nervous system (CNS) diseases, particularly neurodegenerative disorders like Alzheimer's disease (AD), is a critical global health priority. Biotherapeutics, such as monoclonal antibodies (mAbs) and RNA-based therapies, have shown potential for treating brain disorders. However, their clinical progress is limited by their difficult access to their brain targets. At the preclinical level, nanotechnology has been shown, to help these molecules overcome the biological barriers that imped their adequate brain delivery. This review highlights advances in this area and the challenges for the translation to the clinic. Key nanotechnology-based strategies, such as surface modifications utilizing endogenous protein corona, functionalization with targeting ligands, therapeutic ultrasound-mediated microbubble oscillation were particularly analyzed. Additionally, in line with the focus of the Special Issue, this review integrates the concept of chronotherapy, with a focus on AD treatment, highlighting the idea that, by aligning nanoparticle (NP)-based drug delivery with circadian rhythms, it may be possible to improve therapeutic outcomes. Finally, the article analyzes current strategies in CNS drug delivery in clinical trials and provides future directions within this frame, notably in the area of AD.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivatives
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.addr.2025.115606
